The authors would like to thank Michael Eubank for his assistance with the query of the MSKCC institutional database.
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older
Article first published online: 19 APR 2013
© 2013 American Cancer Society
Volume 119, Issue 14, pages 2574–2581, 15 July 2013
How to Cite
Feldman, D. R., Voss, M. H., Jacobsen, E. P., Jia, X., Suarez, J. A., Turkula, S., Sheinfeld, J., Bosl, G. J., Motzer, R. J. and Patil, S. (2013), Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer, 119: 2574–2581. doi: 10.1002/cncr.28025
The first 2 authors contributed equally to the manuscript.
- Issue published online: 1 JUL 2013
- Article first published online: 19 APR 2013
- Manuscript Accepted: 7 JAN 2013
- Manuscript Revised: 21 DEC 2012
- Manuscript Received: 2 NOV 2012
- germ cell tumors;
- testicular cancer;
- age over 50;
- primary site;
Germ cell tumors (GCTs) primarily affect adolescent and young adult men. Detailed clinical and treatment characteristics in older men are lacking.
Patients with GCT seen over a 20-year period at Memorial Sloan-Kettering Cancer Center were identified. Primary tumor site and histology were compared for patients aged ≥ 50 years at diagnosis versus younger men. For patients aged ≥ 50, individual chart review was performed and treatment delays, changes, and toxicities were recorded for those treated with first-line chemotherapy.
Of 4235 diagnoses of GCT, 3999 (94.4%) were made at age < 50 versus 236 (5.6%) at age ≥ 50. Compared with patients diagnosed before age 50, older men more frequently had seminoma (62.7% versus 36.7%) and less frequently, nonseminoma (34.7% versus 63.2%) (P < .0001). Predominant histology switched from nonseminoma to seminoma around age 35. Distribution of primary sites also differed for older versus younger men (testis: 89.4% versus 92.9%; retroperitoneal: 3.8% versus 0.7%; CNS 0% versus 1.7%) except for mediastinal primary tumors, which remained constant across age groups. Fifty patients age ≥ 50 received first-line platinum-based chemotherapy; 30 experienced complications leading to treatment discontinuation, delay ≥ 7 days, or regimen change. Twenty-two (44%) patients experienced neutropenic fever, 6 despite prophylactic growth factor support. Estimated 5-year survival for chemotherapy-treated patients was 84.9%.
Men aged ≥ 50 years comprise less than 10% of GCT diagnoses and have distinct clinical and histological characteristics as compared with younger patients. Although complications from chemotherapy occur frequently in older men, prognosis remains excellent when risk-directed treatment is administered with curative intent. Cancer 2013;119:2574–2581. © 2013 American Cancer Society.